ABT-263 (Navitoclax)

Catalog No.S1001

ABT-263 (Navitoclax) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

Price Stock Quantity  
USD 400 In stock
USD 120 In stock
USD 200 In stock
USD 370 In stock
USD 970 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

ABT-263 (Navitoclax) Chemical Structure

ABT-263 (Navitoclax) Chemical Structure
Molecular Weight: 974.61

Validation & Quality Control

Cited by 36 publications:

13 customer reviews :

Quality Control & MSDS

Related Compound Libraries

ABT-263 (Navitoclax) is available in the following compound libraries:

Bcl-2 Inhibitors with Unique Features

  • Selective Bcl-2 Inhibitor

    ABT-199 (GDC-0199) Bcl-2-selective, Ki<0.01 nM.

  • Bcl-2 Inhibitor in Clinical Trial

    Obatoclax Mesylate (GX15-070) Phase II for leukemia, lymphoma, myelofibrosis, and mastocytosis.

  • Newest Bcl-2 Family Activator

    BAM7 Direct and selective activator of proapoptotic Bax with EC50 of 3.3 μM.

  • Classic Bcl-2 Inhibitor

    ABT-737 BH3-mimetic inhibitor, Bcl-xL, EC50=78.7 nM; Bcl-2, EC50=30.3 nM; Bcl-w, EC50=197.8 nM.

Product Information

  • Compare Bcl-2 Inhibitors
    Compare Bcl-2 Products
  • Research Area
  • Inhibition Profile

Product Description

Biological Activity

Description ABT-263 (Navitoclax) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.
Targets Bcl-xL [1]
(Cell-free assay)
Bcl-2 [1]
(Cell-free assay)
Bcl-w [1]
(Cell-free assay)
A1 [1]
(Cell-free assay)
Mcl-1 [1]
(Cell-free assay)
IC50 <=0.5 nM(Ki) <=1 nM(Ki) <=1 nM(Ki) 354 nM(Ki) 550 nM(Ki)
In vitro ABT-263 is structurally related to ABT-737; it is a disruptor of Bcl-2/Bcl-xL interactions with pro-apoptotic proteins. Overexpression of the prosurvival Bcl-2 family members is commonly associated with tumor maintenance, progression, and chemoresistance. [1] ABT-263 displays the protection afforded by overexpression of Bcl-2 or Bcl-xL with EC50 values of 60 nM and 20 nM, respectively. [1] A wide range of cellular activity is observed with ABT-263 having a 50% growth inhibition (EC50) of 110 nM against the most sensitive line (H146), whereas its activity in the least sensitive line (H82) results in an EC50 at 22 μM. All four cell lines with EC50 values of <400 nM (H146, H889, H1963, and H1417) are also highly sensitive to ABT-737, and the two most resistant lines (H1048 and H82) are similarly resistant to ABT-263. [2]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
EoL-1-cellMVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MofETWM2OD1yLkCwOlY6KM7:TR?=MmPIV2FPT0WU
MV-4-11M1\zOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4L0ZmlEPTB;MD6wNVU5PiEQvF2=M3;IO3NCVkeHUh?=
NKM-1NX3pT5lpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX\JR|UxRTBwMEG2PVkh|ryPNWqxcpMyW0GQR1XS
ML-2NEDGd5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml\YTWM2OD1yLkCxPVg{KM7:TR?=NYWySZFOW0GQR1XS
BV-173M3\0dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnPhTWM2OD1yLkCyN|E1KM7:TR?=M3v6SnNCVkeHUh?=
RS4-11M3j2R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4nDR2lEPTB;MD6wNlU5PyEQvF2=MV;TRW5ITVJ?
HL-60MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXfBelNzUUN3ME2wMlAzQTB6IN88US=>MkO4V2FPT0WU
KY821M4Sw[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX3JR|UxRTBwMEK5O|Uh|ryPNUPZbZg3W0GQR1XS
ECC10M1rY[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2LyN2lEPTB;MD6wN|c6OiEQvF2=NE\OPJBUSU6JRWK=
NCI-H720MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUP0e3I4UUN3ME2wMlA1ODFzIN88US=>MnHNV2FPT0WU
QIMR-WILMn3ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVvJR|UxRTBwMESyPFch|ryPMVfTRW5ITVJ?
KG-1NY\KeFhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFnzT4tKSzVyPUCuNFQ1QDZizszNM120e3NCVkeHUh?=
TGWMo\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWDMdVg5UUN3ME2wMlA1PjN|IN88US=>MVrTRW5ITVJ?
ATN-1NXXsSVlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX3ZNmE2UUN3ME2wMlA1PzN|IN88US=>M4\1PXNCVkeHUh?=
RH-18MmH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYHJR|UxRTBwME[wOFgh|ryPMWjTRW5ITVJ?
EW-18MmLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVLJR|UxRTBwME[4OFEh|ryPM{jRZ3NCVkeHUh?=
NB17MkD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGHJXnVKSzVyPUCuNFcyOjRizszNMn;5V2FPT0WU
SK-NEP-1MmfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlXETWM2OD1yLkC3NlE{KM7:TR?=M1jySXNCVkeHUh?=
P12-ICHIKAWANFP4XmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYTJR|UxRTBwMEe3O|gh|ryPMWXTRW5ITVJ?
KARPAS-45MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmPtTWM2OD1yLkC3PFE2KM7:TR?=MY\TRW5ITVJ?
EW-3M1fLfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2q2T2lEPTB;MD6wPFA2OyEQvF2=NH7JOGFUSU6JRWK=
NB13M4PDcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUXJR|UxRTBwMEiyNFMh|ryPMlq3V2FPT0WU
NCI-H209MmO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWnNUWdPUUN3ME2wMlA5PzB2IN88US=>MXzTRW5ITVJ?
NCI-H1092NYLae3llT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4rZO2lEPTB;MD6xNFI4PSEQvF2=M4XQeXNCVkeHUh?=
NH-12MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYrIVldQUUN3ME2wMlExPzR2IN88US=>M2L3dnNCVkeHUh?=
697NXjYWng5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUjJR|UxRTBwMUC4N|kh|ryPM17CUXNCVkeHUh?=
KE-37Mk[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mkj6TWM2OD1yLkGxN|ch|ryPNXzaSZoyW0GQR1XS
MOLT-4NFvxdY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV\PO3dJUUN3ME2wMlE2OTZ7IN88US=>NX3UN5RLW0GQR1XS
CHP-134NIj2dZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoDGTWM2OD1yLkG2N|A3KM7:TR?=M4TIUnNCVkeHUh?=
D-283MEDM{L6U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXf2cWVjUUN3ME2wMlE4Pjh4IN88US=>MX;TRW5ITVJ?
LU-135MmHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWDYe4xuUUN3ME2wMlE5PTV{IN88US=>M1ziSHNCVkeHUh?=
LU-134-ANH3tW2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1n0R2lEPTB;MD6xPFY4OSEQvF2=M1TYUXNCVkeHUh?=
EM-2MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHLpUXRKSzVyPUCuNVk6OThizszNMlOzV2FPT0WU
LU-139NXTF[FhnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV;BN3UzUUN3ME2wMlIxPDl6IN88US=>MV;TRW5ITVJ?
ALL-POM2fDdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2LmVWlEPTB;MD6yNVk5QCEQvF2=MULTRW5ITVJ?
NB12M2\qPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3X1b2lEPTB;MD6yN|EyPSEQvF2=M33xXXNCVkeHUh?=
KP-N-YNMljRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mli1TWM2OD1yLkKzOVc{KM7:TR?=NITFXllUSU6JRWK=
BENMmHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M17XOGlEPTB;MD6yN|k3QCEQvF2=MXnTRW5ITVJ?
HCC1569MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnzUTWM2OD1yLkK1NVA3KM7:TR?=MVnTRW5ITVJ?
HuO9NIm3[FRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mk\6TWM2OD1yLkK2O|E2KM7:TR?=NHXN[4JUSU6JRWK=
WM-115MnjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF7TZ|VKSzVyPUCuNlc4OzhizszNMV\TRW5ITVJ?
CCRF-CEMM3vWcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWLWVHp6UUN3ME2wMlM{PTJ7IN88US=>MWHTRW5ITVJ?
IST-SL1MljlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnXoTWM2OD1yLkO1N|Q{KM7:TR?=NWTZNY9mW0GQR1XS
BE-13M2\NVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUn5bnJ6UUN3ME2wMlM3PDV7IN88US=>MWPTRW5ITVJ?
COR-L88NUC1WmF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYjJR|UxRTBwM{[1OEDPxE1?MXLTRW5ITVJ?
DOHH-2M{K2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF\tNlJKSzVyPUCuOFExOjNizszNNXT0[VRlW0GQR1XS
A704MmTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVjLRWhtUUN3ME2wMlQzPjdizszNMVnTRW5ITVJ?
KNS-81-FDM1XTO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUHJR|UxRTBwNESwNVch|ryPNXS5WmttW0GQR1XS
RPMI-8226NXTsb3hyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NU[4OW17UUN3ME2wMlQ2PjV{IN88US=>NGHnWpBUSU6JRWK=
TGBC24TKBM2fmW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnTiTWM2OD1yLkS1O|c5KM7:TR?=NWDUfWxlW0GQR1XS
NCI-H1304NFLPTmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoXLTWM2OD1yLkS2NVU4KM7:TR?=NXP6eHc3W0GQR1XS
MOLT-13NET0ZplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1nTVGlEPTB;MD60OlYyOyEQvF2=NGL0TIpUSU6JRWK=
EW-22M4[wN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVHJR|UxRTBwNE[2O|Eh|ryPMVrTRW5ITVJ?
MS-1NYS0eVRvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUX4b25{UUN3ME2wMlQ3QTN|IN88US=>NX3BTpFbW0GQR1XS
RMG-IMWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkTkTWM2OD1yLkS5OFY1KM7:TR?=MXfTRW5ITVJ?
NTERA-S-cl-D1MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWC3VnFoUUN3ME2wMlUxODF7IN88US=>NEO2SnpUSU6JRWK=
NCI-H1048MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlntTWM2OD1yLkWwPVU{KM7:TR?=NFjJbItUSU6JRWK=
SW1417M37FWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVPZXWxkUUN3ME2wMlU2PDN6IN88US=>NIDSZ|BUSU6JRWK=
DBNFLmZ3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlnwTWM2OD1yLkW3NFgh|ryPM1PkPXNCVkeHUh?=
MEG-01M4juUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUf0Vo9EUUN3ME2wMlU5OzJizszNMn7jV2FPT0WU
EW-13Ml30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVfJR|UxRTBwNUizOFEh|ryPMk\pV2FPT0WU
LAMA-84MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3[zdGlEPTB;MD61PVIxPyEQvF2=NIrV[lVUSU6JRWK=
J-RT3-T3-5NHzx[WdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkHmTWM2OD1yLk[wPFA5KM7:TR?=NHfaZ2FUSU6JRWK=
MOLT-16NIrC[o1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYDJR|UxRTBwNkWyOlQh|ryPMVrTRW5ITVJ?
DU-4475MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUDPSXRkUUN3ME2wMlY2PDJ5IN88US=>MVnTRW5ITVJ?
HAL-01M1e2dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1\yXmlEPTB;MD63NlU1QSEQvF2=MkjEV2FPT0WU
RDMnviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{PLUmlEPTB;MD63OVg6QSEQvF2=MojsV2FPT0WU
OAW-28M3njcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUfzO2NEUUN3ME2wMlc5OzdizszNNXTGVoNDW0GQR1XS
HCC38MoH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmqyTWM2OD1yLkiwNVkh|ryPNHXkTlZUSU6JRWK=
NMC-G1NUnWcZZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlPXTWM2OD1yLkixNVIyKM7:TR?=NFq4R3dUSU6JRWK=
EW-16MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmHjTWM2OD1yLkixN|I5KM7:TR?=NX23dVdXW0GQR1XS
DU-145MoLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYTMcIxVUUN3ME2wMlg6QTJ|IN88US=>M13VUHNCVkeHUh?=
HPAF-IIM1rDWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmW5TWM2OD1yLkmyOlI5KM7:TR?=NFSwNVJUSU6JRWK=
A427M4nufWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUjJR|UxRTBwOUOwNlIh|ryPMnPXV2FPT0WU
PA-1NFLrXHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF;1O3lKSzVyPUCuPVU3PDJizszNNVPafWhEW0GQR1XS
OAW-42NUfZXHY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXKwZoN2UUN3ME2wMlk3OTR4IN88US=>NXjLU4g6W0GQR1XS
L-428NGXzWVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXzEeVhIUUN3ME2xMlAyOjVizszNMVvTRW5ITVJ?
COLO-824M37pZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnzMTWM2OD1zLkCxO|A5KM7:TR?=M4TlbXNCVkeHUh?=
P30-OHKNF30cFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml6zTWM2OD1zLkC0Olg5KM7:TR?=NVXR[I0yW0GQR1XS
NCI-H2170NXq1cVJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX3JR|UxRTFwME[yN{DPxE1?NFzMTHRUSU6JRWK=
HCC2998M{DDdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M16w[WlEPTB;MT6wO|E{PSEQvF2=NFnNd3ZUSU6JRWK=
NB14NFjOO4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHSxVpNKSzVyPUGuNVM4PDhizszNMoXrV2FPT0WU
TGBC1TKBM2\5d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnrGTWM2OD1zLkG0NVUzKM7:TR?=MVXTRW5ITVJ?
KP-N-YSNVnreo15T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4qySGlEPTB;MT6xOlI{PiEQvF2=MULTRW5ITVJ?
CAL-120MkfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2f6WmlEPTB;MT6xOlQzQSEQvF2=M4m4fHNCVkeHUh?=
SBC-1Mm\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3HmT2lEPTB;MT6xPVA2OyEQvF2=NFTseGRUSU6JRWK=
C32NWTINIpxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYHuRoFtUUN3ME2xMlE6ODh6IN88US=>M{HsOXNCVkeHUh?=
HCC2157NE\sSVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUXxOm9nUUN3ME2xMlE6PDl2IN88US=>M3XRXXNCVkeHUh?=
COLO-792MkXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NY\o[Jk4UUN3ME2xMlIxODdzIN88US=>M4WzOXNCVkeHUh?=
ES7M1;vO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYXaWmFPUUN3ME2xMlI4QTVzIN88US=>MVPTRW5ITVJ?
HELMXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHzFe3lKSzVyPUGuN|ExOjlizszNNF7IfpZUSU6JRWK=
ES4NFXoc2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFTUUnJKSzVyPUGuN|Q6QThizszNM3mzXHNCVkeHUh?=
NCI-SNU-1NHzXUXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1zBTmlEPTB;MT6zOlU2PSEQvF2=NHT2XphUSU6JRWK=
MDA-MB-415MoHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUjV[o5LUUN3ME2xMlM5QDVizszNM3q2PHNCVkeHUh?=
NCI-H2342NWK4dW9ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1KySmlEPTB;MT60NFI3QSEQvF2=NHX0XoZUSU6JRWK=
NB69Mnj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF;qcWtKSzVyPUGuOFYzPzFizszNNUjHZmFjW0GQR1XS
D-247MGNVHBRmpCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4LyOmlEPTB;MT61NVEzOiEQvF2=NH;1U5dUSU6JRWK=
SCC-4NHzXXGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVfJR|UxRTFwNUm4PFch|ryPMl3MV2FPT0WU
HuH-7MlnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV\JR|UxRTFwNkeyPVMh|ryPNFrEcGNUSU6JRWK=
A388MnTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYPMeGhjUUN3ME2xMlY5PzJ2IN88US=>NVP5VYt1W0GQR1XS
Calu-3Mo[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFfm[GdKSzVyPUGuO|A3QTdizszNMWfTRW5ITVJ?
NCI-H1648MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHrMU5BKSzVyPUGuO|E1OThizszNNILmcFNUSU6JRWK=
NCI-H2052NHG2[G5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlXWTWM2OD1zLkeyNlAyKM7:TR?=MV7TRW5ITVJ?
Ramos-2G6-4C10MmHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUHQRmdHUUN3ME2xMlc{PjV4IN88US=>NF;EelNUSU6JRWK=
DELM17ifmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV\JR|UxRTFwN{S2PVIh|ryPNUDYOm5vW0GQR1XS
SNU-423MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVTMOotiUUN3ME2xMlc5OTV5IN88US=>M4fEfnNCVkeHUh?=
COR-L23NFHrXFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlT3TWM2OD1zLke5PFc1KM7:TR?=MVnTRW5ITVJ?
OMC-1MkLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHK0V3NKSzVyPUGuPFYxOTZizszNM1vYRnNCVkeHUh?=
EW-11M17OSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1XFT2lEPTB;MT65OVY2PyEQvF2=M4SxXHNCVkeHUh?=
HSC-3MoT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn2xTWM2OD1zLkm2N|Y2KM7:TR?=NXf0V2UyW0GQR1XS
MLMANFXDPHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlnqTWM2OD1zLkm2Olc4KM7:TR?=M4rkWHNCVkeHUh?=
RCM-1NIr1PYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mnv4TWM2OD1{LkCwN|k6KM7:TR?=M{HEPHNCVkeHUh?=
MFE-280NU\rblhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVjJR|UxRTJwMEK4OFgh|ryPNGTmco9USU6JRWK=
ES8MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGHFW|hKSzVyPUKuNlU1PzFizszNM3eybnNCVkeHUh?=
TE-11MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnPITWM2OD1{LkK5OFc{KM7:TR?=MXPTRW5ITVJ?
HuO-3N1MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYfJR|UxRTJwNEi3PEDPxE1?MlfiV2FPT0WU
MHH-NB-11MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVzJR|UxRTJwNUGxOVgh|ryPNWDQfGVSW0GQR1XS
TGBC11TKBMlu2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1fxfGlEPTB;Mj61O|Y5OSEQvF2=NV;TNJZoW0GQR1XS
HOP-92MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoriTWM2OD1{LkW4O|Q{KM7:TR?=M2fUVXNCVkeHUh?=
IGR-1MkDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXHJR|UxRTJwNkKwN|Uh|ryPNIr5ZY1USU6JRWK=
GOTOMUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3qxT2lEPTB;Mj62OVM4PyEQvF2=NH:zZYFUSU6JRWK=
NCI-H1650NIf4TYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXHJR|UxRTJwN{KyNVUh|ryPMlzpV2FPT0WU
NCI-H1581MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFPVXphKSzVyPUKuO|k3QDFizszNMXzTRW5ITVJ?
NCI-H2405MonTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGDETZNKSzVyPUKuPFI4QDJizszNM2jsbXNCVkeHUh?=
U-118-MGMoL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXzxW3NqUUN3ME2yMlk3PDlzIN88US=>MXzTRW5ITVJ?
DoTc2-4510M1ziVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHfwPYpKSzVyPUOuNFE1OTdizszNMUPTRW5ITVJ?
NCI-H596M37BXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoXJTWM2OD1|LkC0PVk4KM7:TR?=NWDhcnZPW0GQR1XS
MPP-89MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{\xcWlEPTB;Mz6wOVY3PiEQvF2=MYjTRW5ITVJ?
GCIYMX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4niOWlEPTB;Mz6yNFQ6OSEQvF2=MVrTRW5ITVJ?
SW626MnvkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVfJR|UxRTNwMkS1OFMh|ryPMlvwV2FPT0WU
OCI-AML2MlTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXnNOYRvUUN3ME2zMlMyOjd{IN88US=>NXT5XXhNW0GQR1XS
NBsusSRM1vUXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXjJR|UxRTNwM{S5N|gh|ryPM2nCZXNCVkeHUh?=
AN3-CAMX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVfJR|UxRTNwNESyN|gh|ryPNG\BbWRUSU6JRWK=
EFM-19MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoSyTWM2OD1|LkS4N|M6KM7:TR?=M3nRT3NCVkeHUh?=
RVH-421MlW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYLJR|UxRTNwNU[4O|ch|ryPNXz1ZoZ5W0GQR1XS
5637MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWXLe|hnUUN3ME2zMlYyOTB|IN88US=>MVTTRW5ITVJ?
PANC-08-13MoD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVOxVHdZUUN3ME2zMlY{PDd{IN88US=>NGPpcWZUSU6JRWK=
H9MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIXnWIZKSzVyPUOuOlcyPDRizszNMUDTRW5ITVJ?
KARPAS-299MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHPoVZhKSzVyPUOuOlc{PjFizszNMWXTRW5ITVJ?
TE-5NVm5cpZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH;HWlJKSzVyPUOuO|A4ODlizszNMVHTRW5ITVJ?
NOS-1NInqO2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYPJR|UxRTNwN{m4N|Qh|ryPMVjTRW5ITVJ?
HHNYGzXWpkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEPrNY5KSzVyPUOuPFM5PjhizszNMXXTRW5ITVJ?
769-PMXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXHJR|UxRTNwOEm1NUDPxE1?NIi2PXRUSU6JRWK=
CHP-212M2TsWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYPpNnJVUUN3ME2zMlkzPTR7IN88US=>NYLST2RtW0GQR1XS
NCI-H82NHfaXWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHLXZWpKSzVyPUOuPVU6OzZizszNNEXOWXZUSU6JRWK=
Mo-TNX7RSYlRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFjUb|RKSzVyPUSuNFQ{OTJizszNMnn6V2FPT0WU
BB65-RCCNHPrOIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1y3VWlEPTB;ND6wOFM6QSEQvF2=Ml7OV2FPT0WU
SW1990NGToVVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MknXTWM2OD12LkC1PVA5KM7:TR?=MVzTRW5ITVJ?
LK-2Mlf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXXmboJ4UUN3ME20MlEyOjl|IN88US=>NFHNbHZUSU6JRWK=
ES5NFnzSmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXHKW45zUUN3ME20MlE{QTh3IN88US=>NID4WlVUSU6JRWK=
JVM-3NHWxfJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFXQPZlKSzVyPUSuNVgzOjJizszNNGPCWpNUSU6JRWK=
RPMI-7951NXLhZWMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVHFU5lNUUN3ME20MlIzPDF|IN88US=>NVy4boJOW0GQR1XS
Calu-6M1X6R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV;jSZVrUUN3ME20MlI4QDhzIN88US=>NFnzS41USU6JRWK=
LC-2-adM4[0Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYTJR|UxRTRwMkm1Olgh|ryPNF;VcolUSU6JRWK=
SW954MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NICwfGRKSzVyPUSuNlk3PiEQvF2=MlvoV2FPT0WU
H-EMC-SSMVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmLBTWM2OD12LkOxPFMyKM7:TR?=NW\mPWZCW0GQR1XS
ES3NVm5Upo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVTJR|UxRTRwM{W0OFEh|ryPNYPHN3huW0GQR1XS
no-11MnfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmXhTWM2OD12LkO1OVU1KM7:TR?=NVL2UnR6W0GQR1XS
LAN-6MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnOwTWM2OD12LkS1NVg6KM7:TR?=NEe0dFNUSU6JRWK=
FTC-133NI\tTYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4DodmlEPTB;ND61N|k2KM7:TR?=M4L6TXNCVkeHUh?=
8505CNEDFO5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYTJR|UxRTRwNUSyN{DPxE1?NG\Ne2pUSU6JRWK=
SW620NGrVZmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWTJR|UxRTRwNUewOVch|ryPM1LWZXNCVkeHUh?=
BCPAPNH\QSItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWDJR|UxRTRwNkO0PFEh|ryPMlvTV2FPT0WU
SK-LU-1MlqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFHTVmFKSzVyPUSuOlYxQDlizszNNVK4VI5KW0GQR1XS
NCI-H1623Mn[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2\4dmlEPTB;ND63NFIzQCEQvF2=NGG2cJZUSU6JRWK=
C2BBe1MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1vHPWlEPTB;ND63OFAxQCEQvF2=MnXlV2FPT0WU
GP5dNXvtfGZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXLMbmRsUUN3ME20Mlc5Ozh6IN88US=>Ml65V2FPT0WU
NB6M17lU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnvRTWM2OD12Lki2NlA1KM7:TR?=MV;TRW5ITVJ?
MDA-MB-157NECy[IxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHPzPXJKSzVyPUSuPFg4PiEQvF2=MkTEV2FPT0WU
UMC-11MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV[zN5ZsUUN3ME20Mlg5QTZ2IN88US=>NFr5NWVUSU6JRWK=
HCC1419NIfTXZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWrNcXFDUUN3ME20MlkxODZ|IN88US=>NH;LVGRUSU6JRWK=
NCI-H2029NWCyXpZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYjJR|UxRTRwOUSxPFUh|ryPMoiwV2FPT0WU
LXF-289NXPIfZJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MW\JR|UxRTVwMEO3NVkh|ryPMX\TRW5ITVJ?
KINGS-1MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUPJR|UxRTVwMEe3OFQh|ryPMULTRW5ITVJ?
HD-MY-ZM{D0Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXLJR|UxRTVwMkO5Olkh|ryPNV\XPY1iW0GQR1XS
ESS-1NVOzcJJqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVPJR|UxRTVwMkW1PVch|ryPMYHTRW5ITVJ?
GI-1NILHbHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MorlTWM2OD13LkK3PVI3KM7:TR?=MnixV2FPT0WU
RPMI-2650M{LhdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWXJR|UxRTVwM{[xOkDPxE1?M1v2b3NCVkeHUh?=
IA-LMMkTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NW\yO4puUUN3ME21MlM6QDdzIN88US=>MYLTRW5ITVJ?
KP-4NWW2dVFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF\kfY5KSzVyPUWuOFY{OzRizszNMWnTRW5ITVJ?
G-402NEPGO5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXrJR|UxRTVwNUG4OlUh|ryPM1;NXnNCVkeHUh?=
OS-RC-2NFT2dWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3LWfWlEPTB;NT61NlYxPCEQvF2=M1XROHNCVkeHUh?=
NCI-H1155NV\5e2c3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoTCTWM2OD13LkW0PVU2KM7:TR?=NGXybGRUSU6JRWK=
OE19NHXybY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3vHOWlEPTB;NT62PFYzPCEQvF2=NFi3NVNUSU6JRWK=
U-2-OSNFXFZ2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn\DTWM2OD13Lki5NFE{KM7:TR?=M3yzeHNCVkeHUh?=
SCC-15MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXPJR|UxRTVwOUO2OlIh|ryPMUjTRW5ITVJ?
NCI-H630NVL5TFloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUG0TJBxUUN3ME21Mlk6PDB2IN88US=>M3XtdHNCVkeHUh?=
PFSK-1Ml3SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWLJR|UxRTZwMEWyOVkh|ryPMlzwV2FPT0WU
NCI-H1770M1XofWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX\JR|UxRTZwMkC4O|Qh|ryPMln0V2FPT0WU
SK-MEL-3NUn4OnZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVjJR|UxRTZwNEK5NVUh|ryPMlu5V2FPT0WU
LB1047-RCCMn\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MorQTWM2OD14LkS3OlI2KM7:TR?=NF\lSItUSU6JRWK=
NCI-H446M{HL[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{e4OmlEPTB;Nj62NlkzPSEQvF2=NEDXXG9USU6JRWK=
SW780NHS1Z4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUTOW|NiUUN3ME22MlcxOTh3IN88US=>MlLlV2FPT0WU
NEC8M{jLe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3HjZmlEPTB;Nj63OlY{KM7:TR?=MkLaV2FPT0WU
NOMO-1NF7IV5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoDjTWM2OD14Lke4NVEyKM7:TR?=NFS3PJBUSU6JRWK=
COLO-668MoixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1TzNmlEPTB;Nj64OFM5PyEQvF2=MYLTRW5ITVJ?
MC116M{Owe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV;JR|UxRTZwOUO4PVch|ryPMmLhV2FPT0WU
HCC1937MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWjJR|UxRTZwOUmyOVEh|ryPMUPTRW5ITVJ?
NCI-N87M{T0TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH\mPI5KSzVyPUeuNVkzQTNizszNNUi5boJrW0GQR1XS
COLO-320-HSRNYTzRnFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXfJR|UxRTdwMkK3N|gh|ryPMlvCV2FPT0WU
HCC1806M3PRTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnzVTWM2OD15LkK2NFQ1KM7:TR?=NUfxXnpOW0GQR1XS
OVCAR-3NFPQe21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3PIN2lEPTB;Nz6zN|A{QCEQvF2=NIPwVlVUSU6JRWK=
NUGC-3NUTzXYFST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUewUWVXUUN3ME23MlM6Pjl2IN88US=>M17JT3NCVkeHUh?=
SW1783NGGzN|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn\1TWM2OD15LkSzNVc2KM7:TR?=MlvtV2FPT0WU
GCTMmfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmPITWM2OD15LkW2PVA3KM7:TR?=MXrTRW5ITVJ?
NCI-H2126Mmm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEHGPYJKSzVyPUeuO|M3OjVizszNMmjxV2FPT0WU
MEL-HONHy3UWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVnJR|UxRTdwN{ewOVQh|ryPMlW2V2FPT0WU
CAPAN-1MoLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV7JR|UxRTdwN{ezOVch|ryPMljwV2FPT0WU
SW756NVXxfGc4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX;kTnNWUUN3ME23Mlc5OzN|IN88US=>Ml3EV2FPT0WU
SKG-IIIaNX3LfGdET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXrJR|UxRTdwOEG4PVIh|ryPM4nNcHNCVkeHUh?=
HCE-TNW\sUYI5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmLETWM2OD15Lki3O|g{KM7:TR?=NYDicYxqW0GQR1XS
Ca-SkiNGe5WZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2jWd2lEPTB;Nz65PVM5OyEQvF2=M4Xqc3NCVkeHUh?=
COLO-684NEmxZ4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2jrU2lEPTB;OD6wNVgyQCEQvF2=MX;TRW5ITVJ?
KYSE-70NFqwbXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF76dnpKSzVyPUiuNFc4OjlizszNNHXtNFBUSU6JRWK=
TI-73M{TP[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MW\JR|UxRThwMkW4OVEh|ryPMmPuV2FPT0WU
BT-20MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3;3N2lEPTB;OD6yOlA2OiEQvF2=NXfYbnUxW0GQR1XS
MHH-ES-1NF\tcolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUfJR|UxRThwNUG4N|Qh|ryPNFHqc4JUSU6JRWK=
TE-12MlzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUPFTXdKUUN3ME24MlU6QTNzIN88US=>M33QNHNCVkeHUh?=
YH-13NV7SSIZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX7JR|UxRThwNkGwNFgh|ryPMXHTRW5ITVJ?
SF126MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVzlN21pUUN3ME24Mlg{QDZ3IN88US=>NHzBc4VUSU6JRWK=
J82NWjZO2xQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4Sxd2lEPTB;OD65NFA{QCEQvF2=MVPTRW5ITVJ?
RCC10RGBMmfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYflPIVzUUN3ME24Mlk6PTZzIN88US=>NWnZW2xvW0GQR1XS
SK-UT-1M2DLe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFLiZZJKSzVyPUmuNFQ6PDVizszNMXjTRW5ITVJ?
LB2241-RCCNF;rZY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIH2WnVKSzVyPUmuNVkyOzdizszNNVuzV2NDW0GQR1XS
LB996-RCCM3H1Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2mwe2lEPTB;OT6xPVg6KM7:TR?=NGjTZmpUSU6JRWK=
EPLC-272HMYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{P6TWlEPTB;OT6zO|Y2PyEQvF2=MkLMV2FPT0WU
CTV-1MmDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1LDSmlEPTB;OT61OlU{OiEQvF2=NGXNfo1USU6JRWK=
HSC-2NXT0O2IzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHjMVWdKSzVyPUmuOVc2PSEQvF2=NIHwTZpUSU6JRWK=
SK-MEL-28MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV7JR|UxRTlwNkG4PVMh|ryPNEHGT5RUSU6JRWK=
MMAC-SFNFKxeodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mo\ETWM2OD17Lk[4O|Uh|ryPM3ewZnNCVkeHUh?=
CP50-MEL-BMlHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWfJR|UxRTlwN{W3PFIh|ryPM2m3OnNCVkeHUh?=
HT-1080M4\jXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVvJR|UxRTlwN{e3N|kh|ryPNUPtSXdLW0GQR1XS
HEC-1MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVnJR|UxRTFyLkOzOVIh|ryPNGTPOZlUSU6JRWK=
AGSMnX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoDvTWM2OD1zMD6zO|Qh|ryPNGnZfZJUSU6JRWK=
GAMGM4e3U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFfXRpFKSzVyPUGwMlUyPjJizszNMV;TRW5ITVJ?
SW48NFjLVWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3\sV2lEPTB;MUCuOVE5QSEQvF2=M4XWN3NCVkeHUh?=
U031NXT6SHd1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlvhTWM2OD1zMD61PVA5KM7:TR?=MmPmV2FPT0WU
OVCAR-5NWLnUplTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHTk[ZdKSzVyPUGwMlY1OjlizszNNHLWOYFUSU6JRWK=
SF295NU\iPYx6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUXJR|UxRTFyLk[3NFQh|ryPNW\EXWJuW0GQR1XS
BHT-101NFXIRVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlHOTWM2OD1zMD63NVc4KM7:TR?=M2rxRnNCVkeHUh?=
VMRC-RCZM4XkT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{W3emlEPTB;MUGuN|IxOSEQvF2=NUHFWlJ4W0GQR1XS
ACHNNVThUpN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWXJR|UxRTFzLkSyNVEh|ryPNXHpeFhGW0GQR1XS
NCI-H526M3SwXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVXJR|UxRTFzLkWwOFMh|ryPMmDOV2FPT0WU
MN-60M{m4W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2jOR2lEPTB;MUGuOVM6KM7:TR?=NVLZXpJ{W0GQR1XS
NCI-H2291MlXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVnJR|UxRTFzLkW0OlYh|ryPMnz4V2FPT0WU
SCC-25M33HfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVrJR|UxRTFzLke1OVYh|ryPNYHIWIRSW0GQR1XS
SK-MEL-2NHfCUFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYPCPYd6UUN3ME2xNU44PjN5IN88US=>NGfETnZUSU6JRWK=
SN12CM1jmTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXfJR|UxRTFzLkmzOVUh|ryPM{nEUXNCVkeHUh?=
NCI-H69NVPLVlZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFvNVI5KSzVyPUGyMlQzOzRizszNMnv6V2FPT0WU
ME-180NUjSOIZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnuyTWM2OD1zMj63NFU1KM7:TR?=NFftZmZUSU6JRWK=
MC-IXCNVHJe25yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVXJR|UxRTF{Lke1NVgh|ryPMn7aV2FPT0WU
NCI-H2347MlLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWDhclczUUN3ME2xNk44PjF2IN88US=>MV\TRW5ITVJ?
M059JMXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3nBU2lEPTB;MUKuO|czPyEQvF2=MkPQV2FPT0WU
A2058NGD1b3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mm\KTWM2OD1zMj64OlgyKM7:TR?=MorXV2FPT0WU
VA-ES-BJNGG4eWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4jySWlEPTB;MUKuPFc5PSEQvF2=MWXTRW5ITVJ?
Ca9-22MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmPrTWM2OD1zMj65OFUyKM7:TR?=M3HFPXNCVkeHUh?=
KNS-42Mnn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVvjdpBJUUN3ME2xNk46QTh2IN88US=>NGC4bmpUSU6JRWK=
LoVoNYP3VoQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M13tdmlEPTB;MUOuNlMyOyEQvF2=MWXTRW5ITVJ?
AM-38NGjuOZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mmn5TWM2OD1zMz6yOVY3KM7:TR?=M2XEenNCVkeHUh?=
NB5MojHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWO3Ro5kUUN3ME2xN{4{PzV{IN88US=>NF7yOmNUSU6JRWK=
L-363NV;rT|NMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoLpTWM2OD1zMz60NFM{KM7:TR?=MVfTRW5ITVJ?
SK-MEL-30MnvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4e1emlEPTB;MUSuNFY1PSEQvF2=NF\5RVdUSU6JRWK=
NCI-H1563MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWTVUIE1UUN3ME2xOE43ODN7IN88US=>Ml30V2FPT0WU
NCI-H2228NHHQNo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3XxUGlEPTB;MUSuOlA4PyEQvF2=M2jjfHNCVkeHUh?=
MFM-223NXrTT2R4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3XqVWlEPTB;MUWuNVgyOyEQvF2=NIrXXGFUSU6JRWK=
LB831-BLCMl31S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mmq4TWM2OD1zNT6yO|Y4KM7:TR?=M1rUT3NCVkeHUh?=
SW872NGTwN2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUHJR|UxRTF3LkOwPFYh|ryPM{DZNnNCVkeHUh?=
NCI-H522NXnqcZlxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXPv[oJLUUN3ME2xOU4{OzB4IN88US=>NUnBXYJUW0GQR1XS
EW-1NXrPb|NTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVHJR|UxRTF3LkW0OlIh|ryPM3PQOHNCVkeHUh?=
HNNXu3[Fc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnrDTWM2OD1zNT61PVQzKM7:TR?=NGTrU2NUSU6JRWK=
SW837NXHtPHdsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFLqSFlKSzVyPUG1Mlc5PDdizszNM{C1bHNCVkeHUh?=
SCC-9M2TLZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGD4OphKSzVyPUG1MlgyOTRizszNNYXNTVQ6W0GQR1XS
MKN7M{jNeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoruTWM2OD1zNT65O|MzKM7:TR?=NWHN[FNoW0GQR1XS
KYSE-410NX;pOmhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWDJR|UxRTF4LkW5NUDPxE1?NELVSlhUSU6JRWK=
SK-N-DZNIDWUo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYjIUnlHUUN3ME2xOk43OTF4IN88US=>MWTTRW5ITVJ?
COR-L105M1u2TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlO5TWM2OD1zNj62OVI5KM7:TR?=NUTw[lc2W0GQR1XS
LB2518-MELMnnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWj0dYtyUUN3ME2xOk45Ozh7IN88US=>MV;TRW5ITVJ?
OVCAR-4MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXnJR|UxRTF4Lki4OlIh|ryPM{HKUnNCVkeHUh?=
TK10MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUf2dY1SUUN3ME2xOk46PDd|IN88US=>MmGyV2FPT0WU
KNS-62MkHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGWyWlJKSzVyPUG2Mlk4PzdizszNMl\hV2FPT0WU
RPMI-8866M{X2bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHHKcIlKSzVyPUG3MlE4OzJizszNM3PwenNCVkeHUh?=
HuP-T4MoTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV;JR|UxRTF5LkK0PVUh|ryPMn32V2FPT0WU
CGTH-W-1MoLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYrJR|UxRTF5LkWyNVkh|ryPM1HDbXNCVkeHUh?=
T-24Mo\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUXJR|UxRTF5LkWzOFch|ryPMkTnV2FPT0WU
HT-3NXn6fY5MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEPmbFdKSzVyPUG3MlU6OTRizszNM4LaenNCVkeHUh?=
KS-1NIPD[mtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkDJTWM2OD1zNz62O|Mh|ryPMW\TRW5ITVJ?
NCI-H1792M12wWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mm\zTWM2OD1zNz63PVgh|ryPM3jjcnNCVkeHUh?=
ABC-1NWfrWWpYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEjOTWNKSzVyPUG3MlgyPDFizszNNYG5TIdHW0GQR1XS
BPH-1NEHPdmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1nJN2lEPTB;MUiuNVY5PSEQvF2=NE\qUpRUSU6JRWK=
A431NEXCT4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYC0UmhEUUN3ME2xPE41OTJ5IN88US=>Mli3V2FPT0WU
T98GNXzuTHFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M122VGlEPTB;MUiuOVE2PyEQvF2=M2DT[3NCVkeHUh?=
BHYNUfY[mYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXPCblFpUUN3ME2xPE45PjlizszNNY[1blVwW0GQR1XS
Capan-2M{P1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXLJR|UxRTF6LkmwO|gh|ryPMlzPV2FPT0WU
MDA-MB-175-VIIMVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1u2PWlEPTB;MUiuPVIxQSEQvF2=M4r2PHNCVkeHUh?=
CAL-27MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWLJR|UxRTF7LkC0PFch|ryPM1fHc3NCVkeHUh?=
AsPC-1NEnmXlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoK5TWM2OD1zOT64OlU4KM7:TR?=MVLTRW5ITVJ?
KU812MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4nyc2lEPTB;MUmuPVU4OyEQvF2=MXXTRW5ITVJ?
NCI-H441MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkfyTWM2OD1{MD6wNFEh|ryPMYPTRW5ITVJ?
MewoMVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXLJR|UxRTJyLkGyPFgh|ryPNYLYRnB1W0GQR1XS
SK-MEL-24MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NInFUHBKSzVyPUKwMlE1PzdizszNNIKzW5FUSU6JRWK=
NCI-H727MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX;Q[JBxUUN3ME2yNE4zPzB2IN88US=>MofEV2FPT0WU
EKVXM4jIS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV60S25JUUN3ME2yNE43ODZizszNM{PDUHNCVkeHUh?=
RT-112MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYrifGNUUUN3ME2yNE43OTJ{IN88US=>MXrTRW5ITVJ?
CAMA-1MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIW4VVhKSzVyPUKwMlk5ODNizszNMWXTRW5ITVJ?
SW900M1HqWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWXJR|UxRTJzLkCxOFkh|ryPNHv3N5pUSU6JRWK=
NCI-H23NETt[FhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlzzTWM2OD1{MT6xNlc4KM7:TR?=MX;TRW5ITVJ?
SK-PN-DWNGT1NYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3;xUWlEPTB;MkGuNVY1QSEQvF2=NWX2VJZZW0GQR1XS
BB30-HNCMYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mo\CTWM2OD1{MT6yO|Q2KM7:TR?=NUjIbItlW0GQR1XS
VM-CUB-1MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MU\JR|UxRTJzLkO1N|Yh|ryPM3L3Z3NCVkeHUh?=
IST-MEL1M1;6ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1v3UGlEPTB;MkGuN|Y6OiEQvF2=NYn6eFFkW0GQR1XS
CTB-1Mn;2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIjRe2dKSzVyPUKxMlQ4PTVizszNNYfwTo82W0GQR1XS
LCLC-103HMmXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEXPNlBKSzVyPUKyMlE2QDJizszNM37mWnNCVkeHUh?=
PANC-03-27NET3Z4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX7LfINNUUN3ME2yNk42OTZ7IN88US=>Ml;lV2FPT0WU
HTC-C3MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVvJR|UxRTJ{LkW1OVUh|ryPNG\sZoxUSU6JRWK=
TE-8Mn;mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnvnTWM2OD1{Mz6yOVY2KM7:TR?=M3vkfnNCVkeHUh?=
NCI-H292Mo[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWXxcmRGUUN3ME2yOU4{PTN4IN88US=>NVSz[pBPW0GQR1XS
COLO-680NMoHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYPJR|UxRTJ3Lk[zNlkh|ryPMWDTRW5ITVJ?
KYSE-520NGfZU3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHnBW3ZKSzVyPUK1MlY1PCEQvF2=MV7TRW5ITVJ?
NB10MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmLZTWM2OD1{Nj6zNVE4KM7:TR?=NHvVUZFUSU6JRWK=
NCI-H661NUTyW|VFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGnBRoZKSzVyPUK2MlQ4OTNizszNNYO1OYRnW0GQR1XS
GMS-10NGf3ZldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlPWTWM2OD1{Nj64OlM5KM7:TR?=MWnTRW5ITVJ?
NCI-H2122NE\6OGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MljETWM2OD1{Nj65PVk5KM7:TR?=M4HWdHNCVkeHUh?=
OVCAR-8NYm1d2pKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUnnbG9NUUN3ME2yO{4xPjN6IN88US=>NH7kSHJUSU6JRWK=
DJM-1NX72R|U4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHr3coJKSzVyPUK3MlE1PTRizszNNYTDVG53W0GQR1XS
UACC-893MlvLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlyzTWM2OD1{Nz65PFc5KM7:TR?=M2PhWXNCVkeHUh?=
C8166MnyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MW\JR|UxRTJ6Lk[5N|gh|ryPMXrTRW5ITVJ?
NCI-H1693NGX6XlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M17kXGlEPTB;MkiuOlk4PSEQvF2=NUPrPXdbW0GQR1XS
TYK-nuNVi2bpcyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYDJR|UxRTNyLkCzOFUh|ryPMn;wV2FPT0WU
SW1710MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4\D[WlEPTB;M{CuNVI3KM7:TR?=NES0cJhUSU6JRWK=
A375NIr4XWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2G3T2lEPTB;M{CuN|I1OyEQvF2=NHL4fHhUSU6JRWK=
HMV-IINVXweGdWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3rRdmlEPTB;M{GuN|U6OiEQvF2=NV7aU5ZDW0GQR1XS
NCI-H2087NGKybFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGfoOoxKSzVyPUOxMlY{PTJizszNNGi3UVNUSU6JRWK=
CAL-54M2Xk[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml;1TWM2OD1|MT63NlQyKM7:TR?=MoDSV2FPT0WU
HCC70NIPyN2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGO0b3dKSzVyPUOyMlE{QDdizszNMkfaV2FPT0WU
ES1NF;KWW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mo\yTWM2OD1|Mj6zNFYzKM7:TR?=MWHTRW5ITVJ?
NCI-H1355NHf6W4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MW\JR|UxRTN|LkKwOEDPxE1?NGHzbpZUSU6JRWK=
CFPAC-1M4XPWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnvwTWM2OD1|Mz6yN|MzKM7:TR?=NEGwSWVUSU6JRWK=
MKN28MofaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH3GZ|dKSzVyPUOzMlM5ODlizszNMUTTRW5ITVJ?
HDLM-2MmHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYjxTJBkUUN3ME2zN{43QTNzIN88US=>M2L6OnNCVkeHUh?=
PANC-10-05MnXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnH1TWM2OD1|ND6xNFE1KM7:TR?=NE\pdWRUSU6JRWK=
SASMYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4jmVWlEPTB;M{SuOFU3PSEQvF2=NFOyW2NUSU6JRWK=
HCC1395M3fLSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NETrR4lKSzVyPUO0MlcyQDZizszNNHX4RXNUSU6JRWK=
8305CNFj5R2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIPsd5RKSzVyPUO1Mlg1OTVizszNNWnwemlLW0GQR1XS
KM12NWXRXItrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUfJR|UxRTN4Lke1OFch|ryPNH\MUIdUSU6JRWK=
SW1116NUfPPIpCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUXJR|UxRTN5LkW5PVIh|ryPMlTkV2FPT0WU
SK-MEL-1M1LyVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmLzTWM2OD1|OD6zN|g6KM7:TR?=MnrRV2FPT0WU
HCC2218NHjsTpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUfJR|UxRTN6Lk[1NVkh|ryPNFK1XHdUSU6JRWK=
T84MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NY\DfIVGUUN3ME2zPE44PDB7IN88US=>MmDMV2FPT0WU
ETK-1MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{LpeGlEPTB;M{muNFIzKM7:TR?=M4jEdXNCVkeHUh?=
COLO-800MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnXDTWM2OD1|OT6zPFY5KM7:TR?=NEPB[nJUSU6JRWK=
CAL-12TMmHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXPJR|UxRTN7LkWyPFEh|ryPMnHuV2FPT0WU
ACNMX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmXZTWM2OD12MD60PVEyKM7:TR?=MlfoV2FPT0WU
SJSA-1NEfLO5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{LUfWlEPTB;NEGuNVU6PiEQvF2=NWr5TnFiW0GQR1XS
PSN1M2Tzdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXPJR|UxRTRzLkG3OFkh|ryPMlyxV2FPT0WU
D-566MGMVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEfHV2NKSzVyPUSxMlIxQDZizszNMoTVV2FPT0WU
EGI-1NFu5NpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGji[XVKSzVyPUSyMlQzQCEQvF2=Ml7ZV2FPT0WU
A204NFPpd45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWDJR|UxRTR{Lk[zPFgh|ryPMWfTRW5ITVJ?
Saos-2NGPwOWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4DtVGlEPTB;NEKuPFM3QSEQvF2=NXvJdnV{W0GQR1XS
SNU-C2BMUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGG3Z4RKSzVyPUSzMlY5PzhizszNNIHrcmxUSU6JRWK=
HLEM{DoO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIj3c4NKSzVyPUS0MlA5PTZizszNM4[0VHNCVkeHUh?=
SW1463NH;HXppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NY[yTINwUUN3ME20OE46QTdzIN88US=>MV;TRW5ITVJ?
DSH1MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVrJR|UxRTR3LkCwN|Mh|ryPNEjLcG9USU6JRWK=
MCF7MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{XMXGlEPTB;NEWuOVA2OSEQvF2=NW[3R|ZCW0GQR1XS
K5M3HBVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWPJR|UxRTR3Lkm0NFUh|ryPNEHuTm5USU6JRWK=
NCI-H358MkfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVTJR|UxRTR5LkKxOUDPxE1?NEjtVGxUSU6JRWK=
NCI-H2030NU\RR25oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGfjfGpKSzVyPUS3MlI{PzRizszNMkjDV2FPT0WU
SW948MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{LQXmlEPTB;NEeuOFY1KM7:TR?=NHrMVINUSU6JRWK=
BALL-1NF\Xb2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2\YcWlEPTB;NEeuOlE3QCEQvF2=NH76NVVUSU6JRWK=
TE-9M{H0c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIDNc25KSzVyPUS3Mlk2QDFizszNM3HaUnNCVkeHUh?=
SK-N-FIM1nye2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX;jdZQ{UUN3ME20PE4xOzV6IN88US=>NEGyTGpUSU6JRWK=
KALS-1M1PjWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWnJR|UxRTR6LkGyPFkh|ryPMlfkV2FPT0WU
HO-1-N-1MlznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGPkXFVKSzVyPUS4Mlc1PDVizszNNFLwenJUSU6JRWK=
NCI-H2452MkPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIPP[HZKSzVyPUS5MlEyPTJizszNNGDTfVVUSU6JRWK=
OC-314NFW1R3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXXWTIt5UUN3ME20PU43QDN2IN88US=>MWPTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo When ABT-263 is administered at 100 mg/kg/day in the H345 xenograft model, significant antitumor efficacy is observed with 80% TGI and 20% of treated tumors indicating at least a 50% reduction in tumor volume. [2] Oral administration of ABT-263 alone causes complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia. In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 displays modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens. [2]
Features

Protocol(Only for Reference)

Kinase Assay:

[1]

Affinity determination Binding affinities (Ki or IC50) of ABT-263 against different isoforms of Bcl-2 family are determined with competitive fluorescence polarization assays. The following peptide probe/protein pairs are used: f-bad (1 nM) and Bcl-xL (6 nM), f-Bax (1 nM) and Bcl-2 (10 nM), f-Bax (1 nM) and Bcl-w (40 nM), f-Noxa (2 nM) and Mcl-1 (40 nM), and f-Bax (1 nM) and Bcl-2-A1 (15 nM). Binding affinities for Bcl-xL are also determined using a time-resolved fluorescence resonance energy transfer assay. Bcl-xL (1 nM, His tagged) is mixed with 200 nM f-Bak, 1 nM Tb-labeled anti-His antibody, and ABT-263 at room temperature for 30 min. Fluorescence is measured on an Envision plate reader using a 340/35 nm excitation filter and 520/525 (f-Bak) and 495/510 nm (Tb-labeled anti-His antibody) emission filters.

Cell Assay:

[1]

Cell lines SCLC cell lines
Concentrations 0-1 μM
Incubation Time 48 hours
Method

Human tumor cell lines SCLC cell lines are maintained at 37℃ containing 5% CO2. SCLC cell lines are cultured in RPMI 1640 with 10% fetal bovine serum (FBS), 1% sodium pyruvate, 25 mM HEPES, 4.5 g/L glucose, and 1% penicillin/streptomycin. Leukemia and lymphoma cell lines are cultured in RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin. Cells (1-5×10 4) are treated by ABT-263 for 48 hours in 96-well culture plates in a final volume of 100 μL and cytotoxicity is assessed with the CellTiter Glo assay. In vitro cyto toxicity of ABT-263 is assayed.

Animal Study:

[1]

Animal Models C.B.-17 scid-bg or C.B.-17 scid mice
Formulation Formulated in 10% ethanol, 30% polyethylene glycol 400, and 60% Phosal 50 PG
Dosages 100 mg/kg/d
Administration Administered via p.o.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Tse C, et al. Cancer Res. 2008, 68(9), 3421-3428.

[2] Shoemaker AR, et al. Clin Cancer Res, 2008, 14(11), 3268-3277.

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-30)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02520778 Recruiting Recurrent Non-Small Cell Lung Carcinoma|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Ca  ...more Recurrent Non-Small Cell Lung Carcinoma|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer National Cancer Institute (NCI) March 2016 Phase 1
NCT02591095 Recruiting Platinum-resistant or Refractory Ovarian Cancer Centre Francois Baclesse|ARCAGY/ GINECO GROUP|French Canc  ...more Centre Francois Baclesse|ARCAGY/ GINECO GROUP|French Cancer Research Hospital Program January 2016 Phase 2
NCT02143401 Recruiting Recurrent Hepatocellular Carcinoma|Solid Neoplasm|Stage IV Hepatocellular Carcinoma National Cancer Institute (NCI) November 2014 Phase 1
NCT02079740 Suspended Recurrent Colorectal Carcinoma|Recurrent Lung Carcinoma|Recurrent Pancreatic Carcinoma|Solid Neoplasm|Stage III Lung Cancer|Stage III Pancreatic Ca  ...more Recurrent Colorectal Carcinoma|Recurrent Lung Carcinoma|Recurrent Pancreatic Carcinoma|Solid Neoplasm|Stage III Lung Cancer|Stage III Pancreatic Cancer|Stage IIIA Colorectal Cancer|Stage IIIB Colorectal Cancer|Stage IIIC Colorectal Cancer|Stage IV Lung Cancer|Stage IV Pancreatic Cancer|Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer National Cancer Institute (NCI) March 2014 Phase 1|Phase 2
NCT01989585 Recruiting Metastatic Melanoma|Recurrent Melanoma|Solid Neoplasm|Stage IIIA Skin Melanoma|Stage IIIB Skin Melanoma|Stage IIIC Skin Melanoma|Stage IV Skin Mela  ...more Metastatic Melanoma|Recurrent Melanoma|Solid Neoplasm|Stage IIIA Skin Melanoma|Stage IIIB Skin Melanoma|Stage IIIC Skin Melanoma|Stage IV Skin Melanoma National Cancer Institute (NCI) October 2013 Phase 1|Phase 2

view more

Chemical Information

Download ABT-263 (Navitoclax) SDF
Molecular Weight (MW) 974.61
Formula

C47H55ClF3N5O6S3

CAS No. 923564-51-6
Storage 3 years -20℃powder
2 years -80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 100 mg/mL (102.6 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 5% DMSO+corn oil 7mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 4-​[4-​[[2-​(4-​chlorophenyl)​-​5,​5-​dimethyl-​1-​cyclohexen-​1-​yl]​methyl]​-​1-​piperazinyl]​-​N-​[[4-​[[(1R)​-​3-​(4-​morpholinyl)​-​1-​[(phenylthio)​methyl]​propyl]​amino]​-​3-​[(trifluoromethyl)​sulfonyl]​phenyl]​sulfonyl]​-benzamide

Frequently Asked Questions

  • Question 1
    Could you tell me if the catalog number S1001 can go through the hemato-encephalic barrier?

    Answer: According to the paper: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223694/, ABT-263 can not cross brain-blood barrier.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Bcl-2 Products

  • A-1210477

    A-1210477 is a potent and selective MCL-1 inhibitor with Ki and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.

  • MI-773 (SAR405838)

    MI-773 (SAR405838) is an orally available MDM2 antagonist with Ki of 0.88 nM. Phase 1.

  • Venetoclax (ABT-199, GDC-0199)

    Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with Ki of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Phase 3.

    Features:Re-engineered version of ABT-263 (Navitoclax).

  • ABT-737

    ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.

  • UMI-77

    UMI-77 is a selective Mcl-1 inhibitor with Ki of 490 nM, showing selectivity over other members of Bcl-2 family.

  • Obatoclax Mesylate (GX15-070)

    Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with Ki of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

    Features:Potential 1st-in-class small molecule antagonist of Bcl-2 designed to inhibit all relevant Bcl-2 family members, including Mcl-1.

  • TW-37

    TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.29 μM, 1.11 μM and 0.26 μM in cell-free assays, respectively.

  • Sabutoclax

    Sabutoclax(BI-97C1) is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.

  • AT101

    AT101, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.32 μM, 0.48 μM and 0.18 μM in cell-free assays; does not inhibit BIR3 domain and BID. Phase 2.

Recently Viewed Items

Tags: buy ABT-263 (Navitoclax) | ABT-263 (Navitoclax) supplier | purchase ABT-263 (Navitoclax) | ABT-263 (Navitoclax) cost | ABT-263 (Navitoclax) manufacturer | order ABT-263 (Navitoclax) | ABT-263 (Navitoclax) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us